Replies to post #376460 on Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

The scary thing about that line saying they have enough cash for the next year is that the statement seems to have been written on the likelihood that losses will speed up now.

Because if you have nearly $400 million in cash and you just lost $30 million in a very bad quarter, you still would expect to have enough cash for the next three years unless you think losses are only going to get worse, and rapidly.

JT had always pointed to the fact that the branded product in Japan has always retained at least 40 percent of the market (or was it 60 percent?) after generics arrived. But Japan might not have rules favoring generics at every turn as they exist in the U.S. So there might be a very different dynamic at play.

I know KM keeps talking about opportunities: a billion here, a billion there. But realistically, I think we'd all be happy seeing even $50 million or $100 million here or there, just to provide some hope.

[ziploc_1]

Q1 was disappointing, but not the disaster that the present price would imply
-45% of health plans are now exclusively selling Vascepa and volume in those plans has stabilized, albeit with lower margins...This % will go up
-Only 10% of volume for Vascepa comes from non-exclusive health plans and the volume of gV is not increasing.
-Amarin can continue to cut U.S. marketing costs and narrow its losses.
-Amarin present cash is more than enough to fund Europe until they can break even there.
-Q1 was bad...I expect that successive quarters will be better.
-Europe will eventually be profitable and the combo drug will be a success.
-Journal articles on Amarin continue to impress..as we await the Mitigate study findings..